Search Results - "Van Camp, Benjamin"

Refine Results
  1. 1

    The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model by Caers, Jo, Günthert, Ursula, Raeve, Hendrik, Valckenborgh, Els Van, Menu, Eline, Riet, Ivan Van, Camp, Benjamin Van, Vanderkerken, Karin

    Published in British journal of haematology (01-02-2006)
    “…Multiple myeloma (MM) is a malignancy characterised by the accumulation of monoclonal plasma cells in the bone marrow. Different reports indicate the…”
    Get full text
    Journal Article Web Resource
  2. 2

    Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma by Bakkus, Marleen H. C., Bouko, Yasmina, Samson, Diana, Apperley, Jane F., Thielemans, Kris, Camp, Benjamin Van, Benner, Axel, Goldschmidt, Hartmut, Moos, Marion, Cremer, Friedrich W.

    Published in British journal of haematology (01-09-2004)
    “…Summary High‐dose therapy (HDT) and autologous transplantation prolongs remission duration and survival in multiple myeloma (MM), but relapse still occurs at a…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogeneic bone marrow transplantation by Trullemans, Fabienne, Grignard, Ferre, Van Camp, Benjamin, Schots, Rik

    Published in European journal of haematology (01-08-2001)
    “…: Objectives: Severe neurotoxicity is a recognized complication of cyclosporin A (cyclosporine, CSA). Neuroimaging studies typically show reversible brain…”
    Get full text
    Journal Article
  5. 5
  6. 6

    SCR-based ESD protection in nanometer SOI technologies by Marichal, Olivier, Wybo, Geert, Van Camp, Benjamin, Vanysacker, Pieter, Keppens, Bart

    Published in Microelectronics and reliability (01-07-2007)
    “…This paper introduces an SCR-based ESD protection design for silicon-on-insulator (SOI) technologies. SCR devices or thyristors, as they are sometimes better…”
    Get full text
    Journal Article Conference Proceeding
  7. 7

    Plasma Cells in Multiple Myeloma Express a Natural Killer Cell-Associated Antigen: CD56 (NKH-1; Leu-19) by Camp, Benjamin Van, Durie, Brian G.M., Spier, Catherine, Waele, Marc De, Riet, Ivan Van, Vela, Elizabeth, Frutiger, Yvette, Richter, Lynne, Grogan, Thomas M.

    Published in Blood (15-07-1990)
    “…Bone marrow samples from 55 patients with multiple myeloma (MM) and 23 patients with monoclonal gammopa-thy of undetermined significance (MGUS) were evaluated…”
    Get full text
    Journal Article
  8. 8

    Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells by Van Riet, I, De Waele, M, Remels, L, Lacor, P, Schots, R, Van Camp, B

    Published in British journal of haematology (01-11-1991)
    “…Recently we reported the expression of the human natural killer cell associated antigen CD56 (Leu 19/NKH1) in plasma cells of a majority of multiple myeloma…”
    Get more information
    Journal Article
  9. 9

    Extravasation and homing mechanisms in multiple myeloma by Vande Broek, Isabelle, Vanderkerken, Karin, Van Camp, Benjamin, Van Riet, Ivan

    Published in Clinical & experimental metastasis (01-06-2008)
    “…Multiple myeloma (MM) is a malignant B-cell disorder characterized by a monoclonal expansion of plasma cells (PC) in the bone marrow (BM). During the main…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports by Caers, Jo, Fontaine, Christel, Vinh-Hung, Vincent, De Mey, Johan, Ponnet, Gerrit, Oost, Chris, Lamote, Jan, De Greve, Jacques, Van Camp, Benjamin, Lacor, Patrick

    Published in Supportive care in cancer (01-05-2005)
    “…The use of subcutaneous infusion ports has become standard practice to provide a long-term venous access in oncological patients. The aim of this retrospective…”
    Get full text
    Journal Article Web Resource
  12. 12

    Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression by Asosingh, K, De Raeve, H, de Ridder, M, Storme, GA, Willems, A, Van Riet, I, Van Camp, B, Vanderkerken, K

    Published in Haematologica (Roma) (01-06-2005)
    “…Department of Pathobiology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave., NB40, Cleveland, OH 44195, USA. asosink@ccf.org…”
    Get full text
    Journal Article
  13. 13

    Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment by Caers, Jo, Van Valckenborgh, Els, Menu, Eline, Van Camp, Benjamin, Vanderkerken, Karin

    Published in Bulletin du cancer (01-03-2008)
    “…Cancerogenesis is believed to be a multistep process composed of different alterations that drive the transformation of normal human cells into highly…”
    Get more information
    Journal Article
  14. 14
  15. 15

    Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity by Asosingh, Kewal, De Raeve, Hendrik, Menu, Eline, Van Riet, Ivan, Van Marck, Eric, Van Camp, Benjamin, Vanderkerken, Karin

    Published in Blood (15-04-2004)
    “…The active role of angiogenesis during disease progression is well recognized in solid tumors. In hematologic malignancies such as multiple myeloma (MM), it is…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis by Asosingh, Kewal, De Raeve, Hendrik, Van Riet, Ivan, Van Camp, Benjamin, Vanderkerken, Karin

    Published in Blood (15-04-2003)
    “…At clinical presentation, multiple myeloma (MM) is already a well-established disease. The processes involved in earlier stages are, however, unknown. Here the…”
    Get full text
    Journal Article
  19. 19

    Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma by Vanderkerken, Karin, Medicherla, Satya, Coulton, Les, Van Camp, Benjamin, Protter, Andy, Higgins, Linda, Menu, Eline, Croucher, Peter

    Published in Blood (16-11-2006)
    “…The bone microenvironment plays a critical role in supporting the growth and survival of myeloma cells and the development of osteolytic bone disease…”
    Get full text
    Journal Article
  20. 20